Summary of most frequent AE (>2% population)
| QVA149 300/50 μg | Indacaterol 300 μg | Indacaterol 600 μg | Placebo | |
| N=142 | N=141 | N=141 | N=143 | |
| n (%) | ||||
| Total AE | 39 (27.5) | 31 (22.0) | 37 (26.2) | 31 (21.7) |
| Cough | 4 (2.8) | 1 (0.7) | 3 (2.1) | 2 (1.4) |
| Dyspnoea | 2 (1.4) | 2 (1.4) | 4 (2.8) | 4 (2.8) |
| Headache | 7 (4.9) | 2 (1.4) | 6 (4.3) | 2 (1.4) |
| Nasopharyngitis | 1 (0.7) | 6 (4.3) | 2 (1.4) | 5 (3.5) |
| Diarrhoea | 0 (0.0) | 3 (2.1) | 2 (1.4) | 2 (1.4) |
AE, adverse event.